Highlights Outlook Therapeutics, Inc.

Equities

OTLK

US69012T3059

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
9.1 ^USD	+7.95%		+12.48%	+15.48%

Apr. 15	Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC	CI
Apr. 15	Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : Stocks Set for -2-	Mar. 28	DJ
Outlook Therapeutics Reports Secondary Share Offering	Mar. 25	MT
Sector Update: Health Care Stocks Ease Late Afternoon	Mar. 22	MT
Sector Update: Health Care Stocks Ease Friday Afternoon	Mar. 22	MT
Sector Update: Health Care Stocks Steady Pre-Bell Friday	Mar. 22	MT
Outlook Therapeutics Gets EMA Panel Positive Opinion for Wet AMD Treatment -- Shares Rise Pre-Bell	Mar. 22	MT
Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD	Mar. 22	CI
Outlook Therapeutics to Begin Reverse Stock Split for Regaining Nasdaq Compliance	Mar. 12	MT
North American Morning Briefing : S&P 500 Seen -2-	Feb. 16	DJ
Outlook Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 14	CI
Outlook Therapeutics, Inc. Doses First Subject in Norse Eight	Jan. 31	CI
North American Morning Briefing : Intel Drags Down -2-	Jan. 26	DJ
Outlook Therapeutics Says FDA Clarifies Steps for ONS-5010 Study, Enters Securities Purchase Deals	Jan. 23	MT
Outlook Therapeutics Shares Rally Premarket on ONS-5010 Advances	Jan. 23	DJ
Outlook Therapeutics Receives FDA Agreement under Special Protocol Assessment for 90 Day Non-Inferiority Study, NORSE EIGHT	Jan. 23	CI
Outlook Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Dec. 22	CI
Outlook Therapeutics, Inc. Submits Special Protocol Assessment to FDA for Non-Inferiority Study of ONS-5010	Dec. 19	CI
Outlook Therapeutics, Inc. Announces Strategic Organizational Realignment	Dec. 06	CI
Outlook Therapeutics Expects to Refile Biologics License Application for ONS-5010 by End of 2024	Nov. 27	MT
Outlook Therapeutics, Inc. Provides Update on Type A Meetings with FDA	Nov. 02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Outlook Therapeutics, Inc.

Equities

OTLK

US69012T3059

Highlights

Filters